30
Participants
Start Date
December 28, 2018
Primary Completion Date
March 1, 2021
Study Completion Date
March 1, 2021
TDV
TDV subcutaneous injection comprised of 1 molecularly characterized, attenuated dengue virus strain, and 3 chimeric dengue virus strains with potencies of not less than 3.3, 2.7, 4.0, and 4.5 log10 plaque forming units (PFU) per dose of TDV-1, TDV-2, TDV-3, and TDV-4, respectively.
Optimal Research, Peoria
Oregon Health and Science University, Portland
Lead Sponsor
Takeda
INDUSTRY